An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

Affiliation auteursAffiliation ok
TitreAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis
Type de publicationJournal Article
Year of Publication2019
AuteursDutriaux C., Robert C., Grob J.J, Mortier L., Dereure O., Lebbe C., Mansard S., Grange F., Neidhardt E-M., Lesimple T., Machet L., Bedane C., Maillard H., Dalac-Rat S., Nardin C., Szenik A., Denden A., Saiag P.
JournalANNALS OF ONCOLOGY
Volume30
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN0923-7534